Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $46.58 to a high of $47.19. Yesterday, the shares gained 6.5%, which took the trading range above the 3-day high of $45.00...
FibroGen, Inc. (NASDAQ: FGEN) today reported roxadustat has been included on the updated National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration (NHSA)....
Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $41.55 to a high of $44.20. Yesterday, the shares gained 6.5%, which took the trading range above the 3-day high of $41.00...
Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $36.46 to a high of $37.67. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $37.59...
We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating potential claims against FibroGen, Inc. (NASDAQ: FGEN) on behalf of FibroGen stockholders. Our investigation...
Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors who have suffered significant losses to submit their loss now to learn if they qualify to recover their investment losses. The firm is investigating...
Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) investors concerning the Company and its officers' possible violations...
Law Offices of Howard G. Smith announces an investigation on behalf of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) investors concerning the Company and its officers' possible violations...
Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $34.14 to a high of $35.69. Yesterday, the shares fell 4.0%, which took the trading range below the 3-day low of $34.35...
Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....
FibroGen (FGEN) delivered earnings and revenue surprises of 3.39% and 8.13%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...
-- Roxadustat Positive Pooled Phase 3 Efficacy and Cardiovascular Safety Data Presented Last Friday at American Society of Nephrology 2019 Kidney Week
FibroGen (FGEN) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Roxadustat cardiovascular safety comparable to placebo in non-dialysis dependent (NDD) patients, as assessed by Major Adverse Cardiovascular Events (MACE) and MACE+
Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $34.35 to a high of $36.20. Yesterday, the shares fell 6.2%, which took the trading range below the 3-day low of $37.01...
FibroGen, Inc. (NASDAQ:FGEN), today announced results from the Phase 3 HIMALAYAS trial evaluating roxadustat for the treatment of anemia in incident dialysis (ID) patients with chronic kidney disease (CKD),...
Mallinckrodt (MNK) misses on sales but beats on earnings in the third quarter of 2019.
Jazz Pharmaceuticals (JAZZ) beats third-quarter 2019 earnings and revenue estimates and raises its guidance for 2019.
